🩺What is Acne Vulgaris?
The Investigator's Global Assessment (IGA) scale for acne vulgaris is a static 5-point or 6-point ordinal scale used by clinicians to assess acne severity at a single time point. The IGA evaluates the predominant lesion type (comedones, papules, pustules, nodules) and the extent of involvement. It is widely accepted by regulatory agencies (FDA, EMA) as a co-primary endpoint in acne clinical trials alongside lesion counts. Multiple validated IGA variants exist including the IGA for acne (IGA-A) and the Facial IGA (FIGA).
🏥Signs & Symptoms
The following clinical signs and symptoms are commonly assessed when evaluating Acne Vulgaris:
- Over the last week, how itchy, sore, painful or stinging has your skin been?
- Over the last week, how embarrassed or self-conscious have you been because of your skin?
- Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden?
- Over the last week, how much has your skin influenced the clothes you wear?
- Over the last week, how much has your skin affected any social or leisure activities?
- Over the last week, how much has your skin made it difficult for you to do any sport?
- Over the last week, has your skin prevented you from working or studying? If not, how much has your skin been a problem at work or study?
- Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?
- Over the last week, how much has your skin caused any sexual difficulties?
- Over the last week, how much of a problem has the treatment for your skin been (e.g., taking up time, making a mess, or being painful)?
🔬Causes & Etiology
The Investigator's Global Assessment (IGA) scale for acne vulgaris is a static 5-point or 6-point ordinal scale used by clinicians to assess acne severity at a single time point. The IGA evaluates the predominant lesion type (comedones, papules, pustules, nodules) and the extent of involvement. It is widely accepted by regulatory agencies (FDA, EMA) as a co-primary endpoint in acne clinical trials alongside lesion counts. Multiple validated IGA variants exist including the IGA for acne (IGA-A) and the Facial IGA (FIGA).
The Dermatology Life Quality Index (DLQI) was developed by Finlay and Khan in 1994 at the University of Wales College of Medicine. It is a 10-item self-administered questionnaire covering 6 domains: symptoms and feelings (items 1-2), daily activities (items 3-4), leisure (items 5-6), work and school (item 7), personal relationships (items 8-9), and treatment (item 10). Each item is scored 0-3 (0=not at all, 1=a little, 2=a lot, 3=very much), with a maximum total score of 30. Higher scores indicate greater impairment of quality of life. The DLQI has excellent psychometric properties including test-retest reliability (r=0.99), internal consistency (Cronbach alpha 0.83-0.92), and construct validity demonstrated through correlations with disease severity measures and other quality of life instruments. The DLQI has been validated in over 55 languages and in more than 40 different skin diseases including psoriasis, atopic dermatitis, acne, vitiligo, hidradenitis suppurativa, rosacea, and skin cancer. The DLQI is recommended by the European Academy of Dermatology and Venereology (EADV), the International Psoriasis Council, and the Harmonising Outcome Measures for Eczema (HOME) initiative as the core outcome measure for quality of life in dermatology clinical trials.
⚠️Risk Factors
The following factors are known to increase the risk of developing or worsening Acne Vulgaris:
- Comedones (Blackheads/Whiteheads)
- Papules (Pimples without pus)
- Pustules (Pimples with pus)
- Nodules (Deep, hard, painful bumps)
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Acne Vulgaris:
Acne Severity Grading (IGA Scale)
The Investigator's Global Assessment (IGA) scale is a validated tool for grading acne vulgaris severity based on lesion type and count. It provides a standardized 6-point scale from clear (0) to very severe (5).
DLQI — Dermatology Life Quality Index
The Dermatology Life Quality Index (DLQI) is a 10-item, self-administered questionnaire designed to measure the impact of skin diseases on the quality of life of affected individuals. It is the most widely used dermatology-specific quality of life instrument worldwide.
🧬Diagnostic Logic & Scoring Breakdown
The IGA scale grades acne severity from 0 (clear) to 5 (very severe). Grade 0: Clear skin. Grade 1 (Minimal): Rare comedones, few papules. Grade 2 (Mild): Comedones, some papules and pustules. Grade 3 (Moderate): Many comedones, papules, pustules. Grade 4 (Severe): Numerous pustules, occasional nodules. Grade 5 (Very severe): Highly inflammatory with numerous nodules.
📢Clinical Significance & Implications
Acne vulgaris affects approximately 85% of adolescents and young adults. It can lead to permanent scarring and significant psychological distress. The IGA scale is a FDA-accepted endpoint for acne clinical trials and provides standardized severity assessment for clinical decision-making.
🛡️Prevention & Management
Evidence-based prevention and management strategies for Acne Vulgaris include:
- Continue maintenance therapy if previously treated.
- Topical retinoid therapy.
- Continue current management. No change in treatment intensity indicated.
- Review treatment adherence. Optimize topical therapy. Monitor for progression.
- Consider specialist dermatology referral. Review and adjust treatment plan. Assess for systemic therapy.
- Urgent dermatology specialist referral. Consider systemic therapy, phototherapy, or biologic agents. Assess psychosocial impact.
- Immediate tertiary dermatology referral. Consider biologic therapy or hospitalization. Comprehensive psychosocial support.
- The MCID for DLQI varies by skin condition: psoriasis 3-5 points, atopic dermatitis 4-6 points, acne 3-5 points, and hidradenitis suppurativa 4-6 points. A reduction of >=4 points is generally considered a clinically meaningful improvement. A DLQI of 0-1 is considered a "treatment goal" for biologic therapy in psoriasis.
⚡Complications & Prognosis
Without proper management, Acne Vulgaris may lead to the following complications:
Acne vulgaris affects approximately 85% of adolescents and young adults. It can lead to permanent scarring and significant psychological distress. The IGA scale is a FDA-accepted endpoint for acne clinical trials and provides standardized severity assessment for clinical decision-making.
💡 Clinical Assessment Scenario Example
A teenager with 30 comedones, 15 papules, 8 pustules, 2 nodules on the face. Lesion count suggests Grade 4 (severe).
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Acne Vulgaris:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Scoring post-inflammatory hyperpigmentation as active acne.
✅ Correction: Post-inflammatory hyperpigmentation and erythema are residual changes, not active lesions.
❌ Mistake: Scoring unanswered items as missing rather than 0
✅ Correction: According to DLQI scoring guidelines, items left unanswered (not relevant) should be scored as 0. The DLQI should only be considered invalid if more than 2 items are unanswered.
❌ Mistake: Using DLQI to compare across different skin diseases without adjustment
✅ Correction: DLQI scores can be compared across conditions, but the MCID differs by disease. Use disease-specific MCID values for interpreting change scores.
❌ Mistake: Not calculating domain scores in addition to total score
✅ Correction: The DLQI has 6 domain scores that provide clinically useful information about which aspects of quality of life are most affected. Always calculate and review domain scores.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Acne Vulgaris; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: When should isotretinoin be considered?
Isotretinoin is indicated for severe nodulocystic acne (Grade 4-5), acne refractory to oral antibiotics, acne causing scarring, or acne with significant psychological distress.
Q: What is the minimal clinically important difference (MCID) for DLQI?
The MCID for DLQI varies by skin condition: psoriasis 3-5 points, atopic dermatitis 4-6 points, acne 3-5 points, and hidradenitis suppurativa 4-6 points. A reduction of >=4 points is generally considered a clinically meaningful improvement. A DLQI of 0-1 is considered a "treatment goal" for biologic therapy in psoriasis.
Q: Can DLQI be used for children?
Yes, the Children's DLQI (CDLQI) is available for children aged 4-16 years. It uses simpler language and includes a happy/sad face scale. The CDLQI has 10 items matching the adult DLQI and has been validated for pediatric dermatology.
Q: What is the recommended DLQI score for treatment goal in psoriasis?
A DLQI score of 0 or 1 ("no effect on quality of life") is widely accepted as the treatment goal for biologic therapy in psoriasis. This is known as the "DLQI 0/1 response" and is used as a treatment target in the European S3 Guidelines for psoriasis management.
Q: How long does it take to complete the DLQI?
The DLQI takes approximately 2-5 minutes to complete. It is one of the shortest and most efficient quality of life instruments in dermatology. The recall period is "the past week."
📚Evidence-Based References
Medically Reviewed By
Tabeeb+ Medical Review Team
MD, PhD | Dermatology
Expert dermatology review panel.
View editorial & review policy →